Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of January 2023 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

CONTENTS

On January 12, 2023, NLS Pharmaceutics Ltd., or the Registrant, issued two press releases titled: “NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company’s Growing Portfolio of Pre-clinical Compounds” and “NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement.” Copies of these press releases are furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Registrant’s Registration Statements on Form F-3 (File No. 333-268690 and 333-262489), filed with the U.S. Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit Number		Description of Document
99.1		Press release titled: “NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company’s Growing Portfolio of Pre-clinical Compounds.”
99.2		Press release titled: “NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.